Related references
Note: Only part of the references are listed.Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment.
T. Pressiani et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Sorafenib in Clinical Practice: Evidence-Based Use or Abuse?
Michele Basso et al.
HEPATOLOGY (2012)
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
A. Hollebecque et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Jeong Eun Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization
J. -L. Raoul et al.
CANCER TREATMENT REVIEWS (2011)
Field-Practice Study of Sorafenib Therapy for Hepatocellular Carcinoma: A Prospective Multicenter Study in Italy
Massimo Iavarone et al.
HEPATOLOGY (2011)
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction
J. A. Marrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma
Markus Peck-Radosavljevic et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma
Gillian M. Keating et al.
DRUGS (2009)
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial
Lorenza Rimassa et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis
Marcus Alexander Wörns et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2009)
Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
Antonius A. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
Puneeta Tandon et al.
LIVER INTERNATIONAL (2009)
Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
Matthias Pinter et al.
ONCOLOGIST (2009)
Sorafenib - In hepatocellular carcinoma
Dene Simpson et al.
DRUGS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
G D'Amico et al.
JOURNAL OF HEPATOLOGY (2006)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)